Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03095482 · ClinicalTrials.gov registry record · NA
tDCS-Augmented Exposure Therapy for Pathological Fear
A NA study, sponsored by University of Texas at Austin.
- Completed
- Registry status
- NA
- Development phase
- 49
- Enrollment target
NCT03095482: Completed NA study, sponsored by University of Texas at Austin.
NCT03095482 is a NA study that has completed, run by University of Texas at Austin. The registered enrollment target is 49 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03095482, a NA study, has completed, sponsored by University of Texas at Austin.
- COMPLETED
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
Study Summary
This double-blind randomized controlled clinical trial aims to test whether transcranial direct current stimulation (tDCS) can be used to modulate fear extinction learning during exposure therapy for pathological fear, including fear of spiders, snakes, or germs / contamination. Participation takes place over three laboratory visits, including (1) a pre-treatment visit, (2) a treatment and post-treatment visit, and (3) a 1 month follow-up visit. During treatment, participants will receive either 20 minutes of active or sham tDCS, followed by 30 minutes of in vivo exposure therapy.
Primary Outcome
Subjective units of distress from 0 = no fear, to 100 = extreme fear
Interventions
- DEVICE Transcranial Direct Current Stimulation (tDCS)
- BEHAVIORAL In vivo exposure therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2017-01-01 |
| Est. Completion | 2018-09-06 |
| Phase | NA |
What the finished NCT03095482 record still lists
NCT03095482 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Transcranial Direct Current Stimulation (tDCS) is the first listed.
NCT03095482 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03095482 about?
NCT03095482 is a clinical study titled "tDCS-Augmented Exposure Therapy for Pathological Fear". This double-blind randomized controlled clinical trial aims to test whether transcranial direct current stimulation (tDCS) can be used to modulate fear extinction learning during exposure therapy for pathological fear, including fear of spiders, snakes, or germs / contamination. Participation takes ...
What is the current status of trial NCT03095482?
This trial is currently completed. It is a NA study. The enrollment target is 49 participants. The study started on 2017-01-01. Estimated completion is 2018-09-06.
What interventions are being tested in trial NCT03095482?
The interventions under investigation include: Transcranial Direct Current Stimulation (tDCS) (DEVICE), In vivo exposure therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT03095482?
This trial is sponsored by University of Texas at Austin, which has 257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03095482's enrollment target sits among peer trials
49 1379th of 2000 higher than 620 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI